Chimeric Vaccines against Hyper Evolving Pathogens
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against (re)emerging and Tropical Infections Diseases".
Deadline for manuscript submissions: closed (10 February 2024) | Viewed by 3585
Special Issue Editors
Interests: protein biochemistry; therapeutics discovery; immunoinformatics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Chimeric vaccines can be an effective strategy to combat infectious diseases. The conventional examples include the RTS/S vaccine, which the World Health Organization has recommended for pilot implementation against malaria. The chimeric vaccine approach has also been employed in the FDA-approved vaccine BEXSERO against Neisseria meningitidis serogroup B. BEXSERO includes the chimeric fused antigen of Neisserial Heparin Binding Antigen from strain NZ98/254 and accessory protein 953 from strain 2996. The fusion protein of factor H binding protein from strain MC58 and accessory protein 936 from strain 2996 is also included in BEXSERO. The chimeric vaccine enabled the efficient representation of antigenic repertories and resolved a “deadlock” on vaccine development for malaria and Neisseria meningitidis serogroup B.
This Special Issue invites high-quality research in the development of chimeric vaccine and epitope variations in the newer strains/serotypes of various pathogens. This will include immune determinant polymorphisms’ epidemiology, computational design/screening, mice studies, rational vaccine design and development, immune cell type response and field studies.
Dr. Yash Gupta
Dr. Manish Manish
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multi-epitopic vaccine
- vaccine design
- reverse vaccinology
- potential vaccine candidate
- epitope-scaffolding
- epitope-mapping
- epitope grafting
- multi-graft scaffolding
- immunoinformatics approach
- immunization
- rational design
- structural vaccinology
- immunogen design
- immuno focusing
- protein engineering
- antiviral immunotherapy
- antibody engineering
- antibodyomics tools
